Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LM-299 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on LM-299, a putative bispecific antibody targeting PD-1 and VEGF (May 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LM-299 | LM 299|LM299 | PD-L1/PD-1 antibody 132 VEGF Antibody 15 | Limited information is currently available on LM-299, a putative bispecific antibody targeting PD-1 and VEGF (May 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06650566 | Phase Ib/II | LM-299 | Study of LM-299 in Subjects Advanced Malignant Tumors | Recruiting | AUS | 1 |